In the run up to the Global Hepatitis Summit 2018, new guidelines for the management of hepatitis C should come under scrutiny – for financial conflict of interest and quality of evidence.
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.
Because we're still not sure exactly what causes dementia, finding a treatment is difficult.
The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company's products.
The view of many doctors that “I don’t let myself be influenced” might be the biggest barrier to change.
Just because they can't prescribe medications that does not mean nurses have no influence on important decisions for patient care.
Five new European studies say dementia occurrence is stable or falling. Our panic may have been unnecessary.